Inhaled Technosphere Insulin in Children with Diabetes: The INHALE-1 Extension Study
The INHALE-1 extension phase showed no safety concerns. Although HbA1c levels deteriorated slightly during the study, in view of the safety profile and increased patient satisfaction in the RCT portion of the trial, TI may be a useful treatment option for some pediatric patients with diabetes, particularly for those who choose not to or are unable to use an AID system.
Authors
- Patrick C. Hanley (ORCID: https://orcid.org/0000-0003-4298-7555)
- KRISTINA COSSEN
- Joanna Kramer
- Jamie Wood
- Steven M. Willi
- Lauren Kanapka
- for the INHALE-1 Study Group
- Michael Tansey
- Perrin C. White
- Kathleen E. Bethin
- Roy W. Beck
- Anna Cymbaluk
Institutions
- Alfred I. duPont Hospital for Children (US)
- Children's Hospital of Philadelphia (US)
- Children's Hospital of Los Angeles (US)
- Emory University (US)
- Medical College of Wisconsin (US)
- Community Health Systems - Dupont Hospital (US)
- University of Florida (US)
- Rady Children's Hospital-San Diego (US)
- Nemours Children's Health System (US)
- Buffalo Medical Group (US)
- Jaeb Center for Health Research (US)
- Iowa Diabetes and Endocrinology Research Center (US)
- Rainbow Babies & Children's Hospital (US)
- University at Buffalo, State University of New York (US)
- The University of Texas Southwestern Medical Center (US)
Publication Details
- Journal
- Diabetes Technology & Therapeutics
- Published
- 2026-02-04
- DOI
- https://doi.org/10.1177/15209156261420176
- Primary Topic
- Inhalation and Respiratory Drug Delivery
- Type
- article
- Field-Weighted Citation Impact
- 0.00